Careers
Submit an RFI/RFP

Other Speciality Populations

Clearer oversight. Greater efficiency. Lower costs. Minimised risk

Developed through 20 years’ global industry experience, our advanced technology is empowering all kinds of trial teams to make better-informed decisions and streamline efficiency.

Deep understanding across multiple disciplines

While our primary therapeutic experience is in oncology, we have other specialty therapeutic experience in the following areas:

  • Autoimmune Disease
  • Clinical Pharmacology
  • Congenital Disorders
  • Endocrine/Metabolic
  • Genitourinary
  • Hepatobilary
  • Musculoskeletal
  • Women’s Health

Our expert’s deeper level of understanding across multiple disciplines with complex study designs, innovative protocols, advanced therapies, or specialty populations has provided sponsors with trial success.

Contact us

Why work with us?

Helping you succeed in your project

400

Early phase clinical trials

Our solutions are ready when you are

100

First in human trials

Cmed has successfully supported over 100 First In Human (FIH) studies.

81

Radiopharmaceutical site relationships

Extensive experience of supporting sponsors through RP trials

Examples

Personalised medicine designs

Interaction designs

Enrichment design

Adaptive enrichment designs

Marker strategy designs

Umbrella trials

Basket trials

Platform trials

Supporting Case Studies

CASE STUDIES

Spotlight
Challenges in Glioblastoma Studies
Case Study
Rare Diseases: Phase I First In Human Study on Wilson's Disease
Case Study
Rare Diseases: Phase II Primary Biliary Cholangitis
View more

How quickly Cmed collectively got the study up and running with our first SIV and FPI likely to be ahead of the planned date. It has ‘mes merized the investors’.

…I wanted to extend my thanks from a DM perspective to the entire team for the effort and work you have put in throughout the year, to deliver something that is hugely complex and should have a big impact in the future. Although we have been impacted by COVID, you have all managed to keep some positivity and continue to drive forward at each timepoint and for this I am extremely thankful.”

How quickly Cmed collectively got the study up and running with our first SIV and FPI likely to be ahead of the planned date. It has ‘mesmerized the investors’.

Thanks to all of you for your hard work and efforts. The project is going very well and overall, the Sponsor is very happy.

Get in touch

Let’s support you on your next project

    Related services

    Other ways we support you